Developing AI that estimates blood biomarkers from ECG data.
2 sources · checked 1 time, last 39m ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
Source 1 reports $145,000 from Seoul National University Technology Holdings; the more specific Source 2 reports USD 150,000 from Seoul Techno Holdings, which is used.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed | $145K | 2026-10-08 | not stated | No recent discussion |
2 sources · checked 1 time, last 39m ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 2 sources
Source 1 reports $145,000 from Seoul National University Technology Holdings; the more specific Source 2 reports USD 150,000 from Seoul Techno Holdings, which is used. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: en.wowtale.net, nstartup.me·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 2 sources·[ AGENT ]company research by the Firecrawl agent | ||||
Wavena builds AI that uses a short ECG to estimate many blood-test biomarkers without drawing blood, for hospitals, clinics, consumers and veterinary care.
Wavena says its 10-second ECG can estimate more than 30 blood biomarkers without a blood draw, addressing conventional laboratory workflows that can take about 120 minutes and aiming to support action within 30 minutes. Its seed investment from Seoul Techno Holdings and TIPS selection provide additional R&D support for expanding its clinical data and dialysis algorithms, while the company reports more than 4 million matched ECG-blood records and AUROC scores of 0.89-0.92 for nine key biomarkers.
Checked against 8 sources today
Also named as backers in company research: Tech Incubator Program for Startup (TIPS)